As previous studies28 suggest that larger CH mutations are more strongly associated with adverse clinical outcomes, we repeated this analysis with survivors grouped by CH status as no CH, CH < 10% VAF, and CH ≥ 10% VAF (Figure 5). The gene discussed is C4B; the disease is cyclic hematopoiesis.